Kanwal Raghav

8.7k total citations · 4 hit papers
203 papers, 4.3k citations indexed

About

Kanwal Raghav is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kanwal Raghav has authored 203 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Oncology, 84 papers in Pulmonary and Respiratory Medicine and 78 papers in Cancer Research. Recurrent topics in Kanwal Raghav's work include Colorectal Cancer Treatments and Studies (101 papers), Cancer Genomics and Diagnostics (66 papers) and Genetic factors in colorectal cancer (46 papers). Kanwal Raghav is often cited by papers focused on Colorectal Cancer Treatments and Studies (101 papers), Cancer Genomics and Diagnostics (66 papers) and Genetic factors in colorectal cancer (46 papers). Kanwal Raghav collaborates with scholars based in United States, Italy and Japan. Kanwal Raghav's co-authors include Scott Kopetz, Michael J. Overman, Jonathan M. Loree, Arvind Dasari, Funda Meric‐Bernstam, Robert A. Wolff, David G. Menter, Van K. Morris, Cathy Eng and Lee M. Ellis and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Communications.

In The Last Decade

Kanwal Raghav

186 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

2019 383 citations Funda Meric‐Bernstam, Kanwal Raghav et al. profile →
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

2019 365 citations Jonathan M. Loree, Seerat Anand et al. profile →
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

2019 321 citations Rachna T. Shroff, Milind Javle et al. profile →
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

2023 96 citations Kanwal Raghav et al. profile →

Peers

Countries citing papers authored by Kanwal Raghav

Since Specialization

Citations

This map shows the geographic impact of Kanwal Raghav's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kanwal Raghav with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kanwal Raghav more than expected).

Fields of papers citing papers by Kanwal Raghav

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kanwal Raghav. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kanwal Raghav. The network helps show where Kanwal Raghav may publish in the future.

Co-authorship network of co-authors of Kanwal Raghav

This figure shows the co-authorship network connecting the top 25 collaborators of Kanwal Raghav. A scholar is included among the top collaborators of Kanwal Raghav based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kanwal Raghav. Kanwal Raghav is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Consensus guideline for the management of peritoneal mesothelioma 2025 ·Cancer ·Leanne Brown, (unknown), (unknown), David Su, (unknown), Kiran K. Turaga, Craig G. Gunderson, Byrne Lee, Garrett M. Nash, John L. Hays, Kanwal Raghav, Aliya N. Husain, Michael D. Kluger, Marjorie G. Zauderer, Hedy L. Kindler, H. Richard Alexander	0
2	Supplemental Data for A Phase II Study of Talazoparib Tosylate in Advanced Cancer Patients with Somatic and Germline (Not Breast or Ovarian Cancer) Alterations of BRCA1/2, Mutations/Deletions/Amplification in Other Homologous Recombination Repair Pathway Genes and PTEN or PTEN loss 2024 ·Sarina A. Piha‐Paul, Chieh Tseng, Cheuk Hong Leung, (unknown), Daniel D. Karp, Vivek Subbiah, David S. Hong, Siqing Fu, Aung Naing, Jordi Rodón, Milind Javle, Jaffer A. Ajani, Kanwal Raghav, Neeta Somaiah, Gordon B. Mills, Apostolia M. Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric‐Bernstam	1
3	Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort. 2024 ·Journal of Clinical Oncology ·(unknown), Ryan Sun, (unknown), (unknown), Nicole Zhang, Leylah Drusbosky, Christine M. Parseghian, Kanwal Raghav, Scott Kopetz	1
4	First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer. 2024 ·Journal of Clinical Oncology ·Manish Sharma, John H. Strickler, David Sommerhalder, Yasutoshi Kuboki, Ruth Perets, Jonathan Cohen, Judith Raimbourg, Takako Eguchi Nakajima, Noboru Yamamoto, Marcia Cruz‐Correa, Bert H. O’Neil, François Ghiringhelli, Kanwal Raghav, Rui Li, (unknown), (unknown), Kevin J. Freise, (unknown), Athanasios Vasilopoulos, John D. Powderly	9
5	Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations 2024 ·npj Precision Oncology ·Sarina A. Piha‐Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D. Karp, Vivek Subbiah, David S. Hong, Siqing Fu, Aung Naing, Jordi Rodón, Milind Javle, Jaffer A. Ajani, Kanwal Raghav, Neeta Somaiah, Gordon B. Mills, Apostolia M. Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric‐Bernstam	4
6	Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination 2023 ·Cancer Research Communications ·(unknown), Jane V. Thomas, Kaysia Ludford, Jason Willis, (unknown), Kanwal Raghav, Benny Johnson, Arvind Dasari, Bryan K. Kee, Christine M. Parseghian, Michael S. Lee, (unknown), Maria Pia Morelli, John Paul Shen, (unknown), Eduardo Vilar, Robert A. Wolff, Scott Kopetz, Michael J. Overman, Van K. Morris	4
7	Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing 2023 ·JCO Precision Oncology ·Stefania Napolitano, Aparna R. Parikh, Jason T. Henry, Christine M. Parseghian, Jason Willis, Kanwal Raghav, Van K. Morris, Benny Johnson, Bryan K. Kee, Arvind Dasari, Michael J. Overman, Raja Luthra, Leylah Drusbosky, Ryan B. Corcoran, Scott Kopetz, Ryan Sun	1
8	Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy 2022 ·Clinical Cancer Research ·Sunyoung Lee, Rachna T. Shroff, Shalini Makawita, Lianchun Xiao, (unknown), Priya Bhosale, (unknown), Ahmed Shalaby, Kanwal Raghav, Shubham Pant, Robert A. Wolff, Milind Javle	19
9	Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience 2022 ·The Oncologist ·(unknown), Jane E. Rogers, Hyunsoo Hwang, Wei Qiao, Lianchun Xiao, Arvind Dasari, (unknown), Van K. Morris, Robert A. Wolff, Kanwal Raghav, Ryan Huey, Christine M. Parseghian, Jason Willis, Scott Kopetz, Michael J. Overman, Benny Johnson	14
10	Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States 2022 ·Cancer ·Brian De, Hop S. Tran Cao, Jean‐Nicolas Vauthey, (unknown), Kelsey L. Corrigan, Kanwal Raghav, Sunyoung S. Lee, Ching‐Wei D. Tzeng, Bruce D. Minsky, Grace L. Smith, Emma B. Holliday, Cullen M. Taniguchi, Albert C. Koong, Prajnan Das, Milind Javle, Ethan B. Ludmir, Eugene J. Koay	5
11	Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy 2022 ·Journal of Clinical Oncology ·Christine M. Parseghian, Ryan Sun, (unknown), Stefania Napolitano, (unknown), (unknown), Jason Willis, (unknown), Kanwal Raghav, Van K. Morris, John Paul Shen, (unknown), Alexey V. Sorokin, Preeti Kanikarla Marie, Eduardo Vilar, Marko Rehn, Agnes Ang, Teresa Troiani, Scott Kopetz	41
12	Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance) 2022 ·Journal of Clinical Oncology ·Kanwal Raghav, Fang‐Shu Ou, Alan P. Venook, Federico Innocenti, Ryan Sun, Heinz‐Josef Lenz, Scott Kopetz	25
13	Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors. 2021 ·Journal of Clinical Oncology ·Kaysia Ludford, Kanwal Raghav, Mariela A. Blum Murphy, Nicole D. Fleming, Douglas A. Nelson, Michael Sangmin Lee, Brandon G. Smaglo, Y. Nancy You, (unknown), Carlos Kamiya-Matsuoka, Selvi Thirumurthi, Craig Messick, Benny Johnson, (unknown), Arvind Dasari, Jane V. Thomas, Wai Chin Foo, Wei Qiao, Scott Kopetz, Michael J. Overman	8
14	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies 2020 ·JNCI Cancer Spectrum ·Joseph M. Unger, Dawn L. Hershman, Raymond U. Osarogiagbon, Anirudh Gothwal, Seerat Anand, Arvind Dasari, Michael J. Overman, Jonathan M. Loree, Kanwal Raghav	75
15	Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis 2020 ·Clinical Cancer Research ·Jenny E. Chu, Benny Johnson, (unknown), Van K. Morris, Kanwal Raghav, (unknown), Howard J. Lim, Daniel J. Renouf, Sharlene Gill, Robert Wolber, Aly Karsan, Scott Kopetz, David F. Schaeffer, Jonathan M. Loree	31
16	Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology 2018 ·BMC Medical Research Methodology ·(unknown), Kanwal Raghav, Daniel M. Halperin, James C. Yao, Michael J. Overman	7
17	Underreporting of Research Biopsies from Clinical Trials in Oncology 2017 ·Clinical Cancer Research ·Christine M. Parseghian, Kanwal Raghav, Robert A. Wolff, Joe Ensor, James C. Yao, Lee M. Ellis, Alda L. Tam, Michael J. Overman	14
18	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer 2017 ·Clinical Cancer Research ·Christine M. Parseghian, Nila U. Parikh, Ji Yuan Wu, Zhi-Qin Jiang, Laura E. Henderson, Feng Tian, Brice Pastor, Marc Ychou, Kanwal Raghav, Arvind Dasari, David R. Fogelman, Αναστασία Κατσιαμπούρα, David G. Menter, Robert A. Wolff, Cathy Eng, Michael J. Overman, Alain R. Thierry, Gary E. Gallick, Scott Kopetz	47
19	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes 2017 ·Clinical Cancer Research ·Jonathan M. Loree, Allan Andresson Lima Pereira, Michael Lam, Alexandra N. Willauer, Kanwal Raghav, Arvind Dasari, Van K. Morris, Shailesh Advani, David G. Menter, Cathy Eng, Kenna Shaw, Russell R. Broaddus, Mark J. Routbort, Yusha Liu, Jeffrey S. Morris, Rajyalakshmi Luthra, Funda Meric‐Bernstam, Michael J. Overman, Dipen M. Maru, Scott Kopetz	201
20	Modeling of Patient-Derived Xenografts in Colorectal Cancer 2017 ·Molecular Cancer Therapeutics ·Αναστασία Κατσιαμπούρα, Kanwal Raghav, Zhi-Qin Jiang, David G. Menter, Andreas Varkaris, Maria Pia Morelli, (unknown), Ji Yuan Wu, Alexey V. Sorokin, Bahar Salimian Rizi, Christopher A. Bristow, Feng Tian, Susan Airhart, Mingshan Cheng, Bradley M. Broom, Jeffrey S. Morris, Michael J. Overman, Garth Powis, Scott Kopetz	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact